drugset / Trial / NCT07607054
A First-in-human Phase I Study to Evaluate EMB-15 in Patients With Locally Advanced or Metastatic Solid Tumors.
NaSequentialOpen-labelTreatment
Summary
The primary purpose of this study is to evaluate safety and tolerability profile of EMB-15, identify the recommended Phase 2 dose(s) (RP2Ds) for EMB-15. Pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and the anti-tumor activity of EMB-15 will also be assessed.
Timeline
- Start
- 2026-05-26
- Primary completion
- 2029-05-31
- Completion
- 2029-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EMB-15 | Unknown | — | — |
Indications
No indication recorded.